Bristol Myers Squibb Company $BMY Stock Bought by Howard Capital Management LLC

Key Points

• Howard Capital Management increased its Bristol Myers Squibb stake by 168.1% in the third quarter, bringing its holdings to 123,882 shares valued at approximately $7.73 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported better-than-expected quarterly results, with $2.04 in earnings per share and $12.97 billion in revenue, while setting fiscal 2026 EPS guidance of $6.75–$7.00. The company also declared a quarterly dividend of $0.63 per share, representing a 4.2% yield.
• The stock recently traded near $59.69, while analysts maintained a consensus “Hold” rating and a $64.88 price target. Positive late-stage drug data support the pipeline, but roughly $43 billion in debt and upcoming patent expirations remain key risks.

Howard Capital Management LLC boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 168.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 123,882 shares of the biopharmaceutical company's stock after acquiring an additional 77,676 shares during the period. Howard Capital Management LLC's holdings in Bristol Myers Squibb were worth $7,730,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of BMY. Primecap Management Co. CA acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter worth about $1,436,115,000. Legal & General Group Plc acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $980,862,000. BlackRock Inc. raised its holdings in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. State Street Corp raised its holdings in Bristol Myers Squibb by 7.3% during the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock worth $6,093,755,000 after acquiring an additional 7,192,724 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Bristol Myers Squibb by 153.8% during the first quarter. SG Americas Securities LLC now owns 8,910,032 shares of the biopharmaceutical company's stock valued at $540,393,000 after purchasing an additional 5,399,407 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.05% of the stock is currently owned by insiders.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Recent late-stage data support the company’s effort to replace revenue from aging medicines. Bristol Myers Squibb reported positive Phase 3 topline results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The breadth of the pipeline could strengthen long-term growth if the programs successfully reach the market. How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
• Positive Sentiment: Admilparant remains potentially viable as a pulmonary-fibrosis treatment despite mixed Phase 3 results, with UBS reportedly maintaining a constructive view. The lower dose met the primary endpoint, preserving some commercial potential. Bristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
• Neutral Sentiment: BMY’s roughly 40% one-year rally has been supported by new medicines, revenue growth and higher earnings guidance. However, its low valuation—about 9.36 times forward earnings—suggests investors remain cautious about whether the new portfolio can justify additional upside. Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
• Negative Sentiment: The company’s approximately $43 billion debt load and looming patent cliff create concerns about future cash flow and dividend growth. Bristol Myers Squibb’s 4.2% yield and 17-year record of dividend increases may be attractive, but investors are questioning whether upcoming launches can offset declining legacy-drug revenue. Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Bristol Myers Squibb Trading Down 1.4%

Shares of NYSE:BMY traded down $0.88 during midday trading on Friday, reaching $59.69. The company's stock had a trading volume of 13,770,205 shares, compared to its average volume of 14,832,782. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a 50 day moving average price of $63.55 and a two-hundred day moving average price of $60.29. The firm has a market capitalization of $121.94 billion, a price-to-earnings ratio of 13.15, a PEG ratio of 0.31 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm's revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.56 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb's payout ratio is presently 55.51%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BMY. Morgan Stanley reiterated an "underweight" rating and set a $41.00 price objective (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday, October 7th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $63.00 price target (up from $61.00) on shares of Bristol Myers Squibb in a research note on Wednesday, September 23rd. Cantor Fitzgerald decreased their price objective on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a "neutral" rating for the company in a research report on Thursday, October 8th. William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday. Finally, UBS Group lowered shares of Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of "Hold" and a consensus target price of $64.88.

Bristol Myers Squibb Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb's portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.